FindTrial
Sign In

Efficacy and safety of aspirin plus cilostazol for patients with intracranial aneurysm and stent: a retrospective study from 2019 to 2022

Efficacy and safety of aspirin plus cilostazol for patients with intracranial aneurysm and stent: a retrospective study from 2019 to 2022

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082536
Enrollment
Unknown
Registered
2024-04-01
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Aneurysm

Interventions

cilostazol (cilostazol 100 mg twice daily):None
clopidogrel (clopidogrel 75 mg daily):None

Sponsors

Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 120 Years

Inclusion criteria

Inclusion criteria: (1) Age = 18 years (2) Diagnosed with intracranial aneurysm and treated with stent-assisted coiling or flow diversion (3) Treated with aspirin 100 mg daily plus cilostazol 100 mg twice daily or clopidogrel 75 mg daily (4) The duration of antiplatelet therapy was longer than 3 months

Exclusion criteria

Exclusion criteria: (1) Co-administered with other antithrombotic agents (2) Severe cardiac, hepatic or renal impairment (3) Impaired coagulation or with coagulopathy

Design outcomes

Primary

MeasureTime frame
major adverse cardiovascular and cerebrovascular events;—

Secondary

MeasureTime frame
Modified Rankin Scale, mRS;—

Countries

China

Contacts

Public ContactYi-Chen Li

Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University

ullyclee@126.com+86 138 5170 6247

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026